0 CHECKOUT

Cough - Pipeline Review, H2 2015

  • ID: 3446761
  • September 2015
  • 92 pages
  • Global Markets Direct
1 of 3

Cough - Pipeline Review, H2 2015

Summary

The report ‘Cough - Pipeline Review, H2 2015’, provides an overview of the Cough’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Cough Overview

Therapeutics Development

Pipeline Products for Cough - Overview

Pipeline Products for Cough - Comparative Analysis

Cough - Therapeutics under Development by Companies

Cough - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Cough - Products under Development by Companies

Cough - Companies Involved in Therapeutics Development

Afferent Pharmaceuticals, Inc.

Ahn-Gook Pharmaceutical Co., Ltd.

Alitair Pharmaceuticals, Inc.

Ario Pharma Ltd

AstraZeneca Plc

AUS Bio Limited

Conrig Pharma ApS

Daewoong Pharmaceutical Co., Ltd.

Glenmark Pharmaceuticals Ltd.

Hydra Biosciences, Inc.

Hyundai Pharmaceutical Co., Ltd.

Infirst Healthcare Limited

Johnson & Johnson

Neos Therapeutics, Inc.

NeRRe Therapeutics Ltd

Orbis Biosciences, Inc.

Patara Pharma, Inc.

Vernalis Plc

Cough - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AF-219 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AG-1321001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AG-1321001-SY - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AGPPC-709 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

benzonatate polacrilex - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCP-05 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCP-06 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCP-07 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCP-08 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

codeine + guaifenesin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CS-1002 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DWJ-1340 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GRC-17536 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

guaifenesin + hydrocodone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

guaifenesin ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HC-030031 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JNJ-39729209 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lesogaberan - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levodropropizine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MD-990 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

orvepitant maleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Cough and Cold - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ST-015 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

XEND-0501 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cough - Recent Pipeline Updates

Cough - Dormant Projects

Cough - Discontinued Products

Cough - Product Development Milestones

Featured News & Press Releases

Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine

Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet

Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept

Apr 29, 2014: Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept

Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications

Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219

Jan 06, 2012: Tris Pharma Announces US Patent Grant Covering Platform Technology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cough, H2 2015

Number of Products under Development for Cough - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015

Cough - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2015

Cough - Pipeline by Alitair Pharmaceuticals, Inc., H2 2015

Cough - Pipeline by Ario Pharma Ltd, H2 2015

Cough - Pipeline by AstraZeneca Plc, H2 2015

Cough - Pipeline by AUS Bio Limited, H2 2015

Cough - Pipeline by Conrig Pharma ApS, H2 2015

Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015

Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015

Cough - Pipeline by Hydra Biosciences, Inc., H2 2015

Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2015

Cough - Pipeline by Infirst Healthcare Limited, H2 2015

Cough - Pipeline by Johnson & Johnson, H2 2015

Cough - Pipeline by Neos Therapeutics, Inc., H2 2015

Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2015

Cough - Pipeline by Orbis Biosciences, Inc., H2 2015

Cough - Pipeline by Patara Pharma, Inc., H2 2015

Cough - Pipeline by Vernalis Plc, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Cough Therapeutics - Recent Pipeline Updates, H2 2015

Cough - Dormant Projects, H2 2015

Cough - Dormant Projects (Contd..1), H2 2015

Cough - Dormant Projects (Contd..2), H2 2015

Cough - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Cough, H2 2015

Number of Products under Development for Cough - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Johnson & Johnson Services, Inc.
  • Procter & Gamble Co.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer Inc.
  • Boehringer Ingelheim GmbH